By Dr. Charles Kamen, MD — Board-Certified Neurologist, LiveWell21, Las Vegas, NV
Albert Einstein College of Medicine (MD, 2011) | Yale-New Haven Hospital Internship (2011–2012) | Loma Linda University Neurology Residency (2015–2018) | ABPN Board Certified
When patients ask me about NAD+ IV therapy, they're usually approaching it from one of two directions. Some have heard the phrase "anti-aging molecule" and are curious whether it lives up to the marketing. Others have done serious reading — they've encountered the work of David Sinclair at Harvard or the research coming out of Washington University in St. Louis — and they want a clinical interpretation.
My answer to both groups starts in the same place: the biology. NAD+ is one of the most well-studied molecules in the history of metabolic science, and the research connecting it to aging, neuroprotection, and brain function is genuinely compelling. But I prescribe it as a neurologist — which means I think about it through a specific lens that most IV wellness providers do not bring to the conversation.
This post is my attempt to give you the honest, mechanistically grounded picture of NAD+ IV therapy for brain health: what NAD+ does, why it matters for the aging brain specifically, what the current research supports, and how I think about its clinical use at LiveWell21 in Las Vegas.
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in every living cell. In its oxidized form (NAD+) and reduced form (NADH), it is central to cellular energy metabolism — specifically to the electron transport chain in the mitochondria, where it shuttles electrons to produce ATP, the cell's primary energy currency.
But NAD+ does far more than fuel energy production. It is also a required substrate for two classes of enzymes with profound implications for aging biology:
The net result: NAD+ levels fall substantially with age. Research by Verdin and colleagues published in Science quantified this decline at roughly 50% between the ages of 40 and 60, with continued decline thereafter.3 And this is not a peripheral finding — it's connected to multiple hallmarks of aging, from mitochondrial dysfunction to genomic instability to impaired cellular stress response.
I want to spend time on this point, because it's where my perspective as a neurologist diverges from the general wellness framing of NAD+.
The brain consumes approximately 20% of the body's energy while comprising only 2% of its mass. Neurons are extraordinarily metabolically demanding cells — they maintain steep ion gradients across their membranes, synthesize neurotransmitters, and sustain synaptic transmission continuously. They are almost entirely dependent on oxidative phosphorylation (mitochondrial ATP production), which requires NAD+ as a cofactor. Unlike many cell types, neurons have very limited capacity for anaerobic energy production. When mitochondrial function falters, neurons suffer disproportionately.
Neurons are also among the longest-lived cells in the body. A neuron born during fetal development may function for 80 or 90 years — accumulating DNA damage, protein aggregates, and mitochondrial dysfunction over that entire period. The cell has no opportunity for the reset that comes with cell division. This means that the DNA repair capacity provided by NAD+-dependent PARPs and the proteostatic maintenance supported by NAD+-dependent sirtuins matter enormously for long-term neuronal survival.
The neurological implications of NAD+ depletion are well-documented at a basic science level:
None of this establishes that NAD+ IV therapy prevents dementia or reverses cognitive decline — I want to be clear about the boundaries of what the current evidence supports. But the mechanistic case for protecting and restoring NAD+ levels as a strategy for brain resilience is scientifically coherent and grounded in established neuroscience.
The research on NAD+ supplementation in humans is still maturing. Most of the foundational work has been done in animal models, where the findings are consistently impressive. Translation to human clinical trials is ongoing, and the results are directionally positive if not yet definitive.
Key areas of human evidence:
Cognitive aging: A 2023 randomized controlled trial published in Nature Aging found that NMN (nicotinamide mononucleotide, a NAD+ precursor) supplementation in older adults improved muscle function, gait speed, and grip strength compared to placebo — markers of biological age and physical resilience. Earlier work from Washington University showed that NMN supplementation increased NAD+ levels in muscle tissue in postmenopausal women with prediabetes, with improvements in insulin sensitivity.5
Neurological disease research: In Alzheimer's disease models, NAD+ restoration has consistently reduced amyloid accumulation and tau pathology, improved mitochondrial function, and extended survival. While these are preclinical findings, they have driven clinical trials that are currently enrolling — including trials evaluating NAD+ precursors in early Alzheimer's disease and mild cognitive impairment.
Substance dependence: One of the earliest clinical applications of high-dose IV NAD+ was in addiction medicine, where practitioners observed that NAD+ infusions helped reduce withdrawal symptoms and cravings in patients recovering from alcohol and opioid dependence. The proposed mechanism involves restoration of neuronal energy metabolism disrupted by chronic substance use. This application has the longest track record of any clinical use of IV NAD+, with decades of anecdotal evidence from addiction treatment centers, though formal randomized trials are limited.
Mental clarity and fatigue: The most consistent feedback I hear from patients following NAD+ infusions is improved mental clarity, better energy, and a reduction in the cognitive fog that many describe as a creeping feature of their 40s and 50s. These are subjective outcomes, and I'm careful about over-interpreting them — but they are consistent, they align with the mechanistic expectations, and they motivate the patients who've experienced them to continue treatment.
The oral NAD+ supplement market has exploded over the last several years. Products containing NMN and NR (nicotinamide riboside) are widely available and have been shown in clinical trials to meaningfully increase circulating NAD+ levels. David Sinclair, whose research helped establish the sirtuin-NAD+ axis, publicly uses NMN supplementation. This is not pseudoscience.
So why prescribe IV NAD+ when oral precursors are available and significantly less expensive?
The answer depends on the clinical context. For patients who are generally healthy, interested in long-term NAD+ support, and have no acute deficiency state, daily oral NMN or NR supplementation is a reasonable and evidence-supported strategy. I often recommend it between IV sessions.
IV NAD+ has specific advantages in certain scenarios:
My clinical approach is to use IV NAD+ for initial loading or acute repletion, and oral precursors for ongoing maintenance — combining the therapeutic intensity of IV delivery with the practicality and cost-effectiveness of oral supplementation.
NAD+ infusions require more time and attention than a basic Myers' Cocktail. The molecule must be administered slowly — typically over 2 to 4 hours depending on the dose — because rapid infusion causes uncomfortable and predictable side effects: chest tightness, a pressure sensation in the head, nausea, and muscle cramping. These effects are not dangerous, but they are unpleasant and entirely avoidable with proper pacing.
For patients new to NAD+ IV therapy, I start at a lower dose and extend the infusion time accordingly. As tolerance is established over the first 2–3 sessions, we can increase the dose and — if desired — shorten the infusion window somewhat. Most patients reach a comfortable maintenance dosing pattern within a few sessions.
The experience during infusion is typically unremarkable once the rate is calibrated: patients sit comfortably, often working or reading. Some describe a mild warmth or tingly sensation. The characteristic effects many report — improved clarity, enhanced mood, physical energy — tend to emerge in the 24–72 hours following the infusion as cellular NAD+ is replenished and metabolic activity responds.
Before your first NAD+ infusion at LiveWell21, we conduct a thorough intake and typically review baseline labs to assess your current metabolic health and identify any contraindications. The decision to use IV NAD+ is a clinical one, made in the context of your complete health picture — not a menu selection.
In my clinical judgment, NAD+ IV therapy is most appropriate for:
NAD+ IV therapy is generally well-tolerated, but it's not appropriate for everyone. We carefully evaluate patients with active malignancy, certain enzyme deficiencies, or specific cardiovascular conditions before recommending it.
NAD+ IV therapy is increasingly available at standalone hydration spas and wellness lounges, many of which operate without direct physician supervision. I want to offer a clear-eyed view of what that distinction means clinically.
When I prescribe NAD+ infusions, I'm doing so within a clinical framework that includes a full neurological assessment, review of your medications (several drug interactions are relevant, including with certain anticonvulsants and psychotropics), baseline lab evaluation, and integration with your broader health strategy. I'm thinking about how NAD+ fits with any neurological findings, what your mitochondrial and metabolic health indicators suggest about your baseline NAD+ status, and how to calibrate dosing to your specific situation.
That's meaningfully different from selecting a "brain boost" package from a menu — even if the molecule being administered is identical.
If you're in Las Vegas and want to explore NAD+ IV therapy within a proper medical framework, I'd welcome the conversation.
Book a Consultation at LiveWell21
Explore our related services:
Complete Guide to IV Nutrition Therapy | IV Therapy vs. Oral Supplements | Peptide Therapy | Hormone Optimization | Advanced Diagnostics
This content is for educational purposes and does not constitute medical advice. Consult a qualified physician before beginning any IV therapy program. Statements about NAD+ IV therapy have not been evaluated by the FDA for disease prevention or treatment.